Rocha-Junior Mauricio Cristiano, Rodrigues Evandra Strazza, Slavov Svetoslav Nanev, Assone Tatiane, Pedreschi Maíra, de La Roque Debora Glenda Lima, Sousa Maisa, Olavarria Viviana, Galvão-Castro Bernardo, da Fonseca Benedito Antonio Lopes, Penalva de Oliveira Augusto César, Smid Jerusa, Takayanagui Oswaldo Massaiti, Casseb Jorge, Covas Dimas Tadeu, Kashima Simone
Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Graduate Program in Biosciences and Biotechnology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Front Med (Lausanne). 2022 Jun 9;9:881630. doi: 10.3389/fmed.2022.881630. eCollection 2022.
Human T cell lymphotropic virus (HTLV) is the caustive agent of two main conditions i. e., the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and the adult T-cell leukemia/lymphoma (ATLL). HTLV diagnosis is based on serological and molecular approaches; however, an accurate and validated method is still needed. The objective of this study was to establish a rapid and sensitive molecular test to confirm and discriminate HTLV 1/2 types. The test validation was performed as a multicentric study involving HTLV confirmation centers throughout Brazil. Proviral DNA was extracted from whole blood and the amplification was performed using in-house designed primer and probe sets targeting the genomic region. An internal control to validate the extraction and amplification was also included. The limit of detection (LoD) of the assay was four copies/reaction for HTLV-1 and 10.9 copies/reaction for HTLV-2. The diagnostic sensitivity of the platform was 94.6% for HTLV-1, 78.6% for HTLV-2, and the specificity was 100% for both viruses. Cross-reactions of the test with human viruses including HAV, HBV, HCV, HIV-1/2, and parvovirus B19 were not observed. During the multicentric validation, the test was used to screen a total of 692 blood samples obtained from previously confirmed HTLV-positive individuals. From these, 91.1% tested positive being concordant with the previously obtained results. In conclusion, our duoplex-RT-PCR-HTLV1 /2 presented adequate efficiency for HTLV-1/2 differentiation showing high sensitivity and specificity. Therefore, it can be a suitable tool for confirmation of suspected and inconclusive HTLV cases, prenatal and pre-transplant diagnosis, in Brazil and in other countries HTLV-endemic countries.
人类嗜T细胞病毒(HTLV)是两种主要疾病的病原体,即HTLV-1相关脊髓病/热带痉挛性截瘫(HAM/TSP)和成人T细胞白血病/淋巴瘤(ATLL)。HTLV的诊断基于血清学和分子方法;然而,仍需要一种准确且经过验证的方法。本研究的目的是建立一种快速且灵敏的分子检测方法,以确认和区分HTLV 1/2型。该检测方法的验证是一项多中心研究,涉及巴西各地的HTLV确认中心。从全血中提取前病毒DNA,并使用针对基因组区域的内部设计引物和探针组进行扩增。还包括一个用于验证提取和扩增的内部对照。该检测方法对HTLV-1的检测限为每反应4拷贝,对HTLV-2为每反应10.9拷贝。该平台对HTLV-1的诊断敏感性为94.6%,对HTLV-2为78.6%,两种病毒的特异性均为100%。未观察到该检测方法与包括甲型肝炎病毒、乙型肝炎病毒、丙型肝炎病毒、HIV-1/2和细小病毒B19在内的人类病毒发生交叉反应。在多中心验证期间,该检测方法用于筛查总共692份先前确诊为HTLV阳性个体的血样。其中,91.1%检测呈阳性,与先前获得的结果一致。总之,我们的双重RT-PCR-HTLV1 /2在HTLV-1/2鉴别方面具有足够的效率,显示出高敏感性和特异性。因此,它可以成为巴西以及其他HTLV流行国家用于确认疑似和不确定HTLV病例、产前和移植前诊断的合适工具。